Astragaloside IV, an active component isolated fromAstragalus membranaceus, suppresses the activation ofERK1/2andJNK/b> , and downregulates matrix metalloproteases (MMP)-2, (MMP)-9in MDA-MB-231 breast cancer cells.
Astragaloside IV(AS-IV) is a saponin from Astragalus membranaceus. Oral administration of AS-IV (10 and 20 mg/kg) significantly attenuated memory impairment and neuroinflammation[3]. High-dose astragaloside IV has a significant protective effect against D-GalN/LPS-induced (D-galactosamine/lipopolysaccharide-induced ) acute liver injury in mice [4]. High doses of astragaloside IV (10, 20, 40 ng/ml) inhibited NSCLC (non-small cell lung cancer ) cell growth[5]. Astragaloside IV inhibited the viability and invasive potential of MDA-MB-231 breast cancer cells, suppressed the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulated matrix metalloproteases (MMP)-2 and -9[6].
搜索
